DiaMedica Therapeutics Inc. Common Stock (DMAC) is a publicly traded Healthcare sector company. As of May 20, 2026, DMAC trades at $5.67 with a market cap of $306.06M and a P/E ratio of -8.07. DMAC moved +1.08% today. Year to date, DMAC is -29.76%; over the trailing twelve months it is +30.45%. Its 52-week range spans $3.19 to $10.42. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces DMAC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
DMAC financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. DMAC recently traded at $5.67. Market cap is $306.06M. P/E ratio is -8.07. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $5.67 |
| Market Cap | $306.06M |
| P/E Ratio | -8.07 |
| EPS | $-0.70 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.42 |
| 52-Week Low | $3.19 |
| Volume | 80.40K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-32.77M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-32.77M | $-0.70 |
| 2024 | $0 | $-24.44M | $-0.60 |
| 2023 | $0 | $-19.38M | $-0.60 |
| 2022 | $0 | $-13.68M | $-0.52 |
3 analysts cover DMAC: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.